TY - JOUR
T1 - Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy
T2 - A comparative study
AU - Maggi, Paolo
AU - Lillo, Antonio
AU - Perilli, Francesco
AU - Maserati, Renato
AU - Chirianni, Antonio
AU - Epifani, G.
AU - Fiorentino, G.
AU - Ladisa, N.
AU - Pastore, G.
AU - Angiletta, D.
AU - Impedovo, G.
AU - Regina, G.
AU - Gargiulo, M.
AU - Ferraro, S.
AU - Ferrara, S.
AU - Grisorio, B.
AU - Maserali, R.
AU - Ravasi, G.
AU - Martignoni, A.
AU - Pellegrino, C.
AU - Fanelli, M.
PY - 2004/4/30
Y1 - 2004/4/30
N2 - Objectives: To evaluate the correlation between antiretroviral therapy (ART) and lesions of the carotid vessels using an ultrasound colour-Doppler technique. Design: A total of 293 HIV-1 infected patients underwent epiaortic vessel ultrasonography: 105 on treatment with protease inhibitors (PI) (group I), 125 PI-naive patients treated with a non-nucleoside reverse transcriptase inhibitor-including regimen (group II), and 63 patients treated with two nucleoside reverse transcriptase inhibitors or naive to ART (group III). Methods: Intima characteristics, pulsation and resistance indexes, and minimal, peak and mean speed were evaluated using a colour power doppler. Atherosclerotic plaques were described. Independent risk factors and values for glycaemia, cholesterolaemia and triglyceridaemia were considered. Statistical analysis included the Wilcoxon tests, the χ2 test, the Cochran Armitage trend test and the Mantel-Haenszel test and, when necessary, logistic regression analysis. Results: Of the 150 group I patients, 55 (52.4%) presented acquired lesions of the vascular wall at ultrasonography, whereas similar lesions were found in 19 out of 125 (15.2%) patients in group II and in nine of 63 (14.3%) in group III. ART, age, smoking and CD4 T-cell count were the main predictive risk factors for vascular lesions. However, the highest significance was with the use of PI. Conclusions: These data confirm the higher prevalence of premature carotid lesions in the PI-treated patients. A periodic ultrasonographic study of the vascular wall should be included in the follow-up of HIV infected patients.
AB - Objectives: To evaluate the correlation between antiretroviral therapy (ART) and lesions of the carotid vessels using an ultrasound colour-Doppler technique. Design: A total of 293 HIV-1 infected patients underwent epiaortic vessel ultrasonography: 105 on treatment with protease inhibitors (PI) (group I), 125 PI-naive patients treated with a non-nucleoside reverse transcriptase inhibitor-including regimen (group II), and 63 patients treated with two nucleoside reverse transcriptase inhibitors or naive to ART (group III). Methods: Intima characteristics, pulsation and resistance indexes, and minimal, peak and mean speed were evaluated using a colour power doppler. Atherosclerotic plaques were described. Independent risk factors and values for glycaemia, cholesterolaemia and triglyceridaemia were considered. Statistical analysis included the Wilcoxon tests, the χ2 test, the Cochran Armitage trend test and the Mantel-Haenszel test and, when necessary, logistic regression analysis. Results: Of the 150 group I patients, 55 (52.4%) presented acquired lesions of the vascular wall at ultrasonography, whereas similar lesions were found in 19 out of 125 (15.2%) patients in group II and in nine of 63 (14.3%) in group III. ART, age, smoking and CD4 T-cell count were the main predictive risk factors for vascular lesions. However, the highest significance was with the use of PI. Conclusions: These data confirm the higher prevalence of premature carotid lesions in the PI-treated patients. A periodic ultrasonographic study of the vascular wall should be included in the follow-up of HIV infected patients.
KW - Antiretroviral therapy
KW - Artheroslerosis
KW - Carotid
KW - Colour-Doppler ultrasonography
KW - HIV
KW - Protease inhibitor
UR - http://www.scopus.com/inward/record.url?scp=2342655870&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342655870&partnerID=8YFLogxK
U2 - 10.1097/00002030-200404300-00010
DO - 10.1097/00002030-200404300-00010
M3 - Article
C2 - 15096805
AN - SCOPUS:2342655870
VL - 18
SP - 1023
EP - 1028
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 7
ER -